Search

Your search keyword '"Karczewski, Marek"' showing total 134 results
Start Over Author "Karczewski, Marek"
134 results on '"Karczewski, Marek"'

1. Impaired Expression of Humanin during Adrenocortical Carcinoma

Author

Blatkiewicz, Małgorzata, primary, Szyszka, Marta, additional, Olechnowicz, Anna, additional, Kamiński, Kacper, additional, Jopek, Karol, additional, Komarowska, Hanna, additional, Tyczewska, Marianna, additional, Klimont, Anna, additional, Wierzbicki, Tomasz, additional, Karczewski, Marek, additional, Ruchała, Marek, additional, and Rucinski, Marcin, additional

Published
2024
Full Text
View/download PDF

6. Assessment of omeprazole and famotidine effects on the pharmacokinetics of tacrolimus in patients following kidney transplant--randomized controlled trial.

Author

Miedziaszczyk, Miłosz, Karczewski, Marek, Grabowski, Tomasz, Wolc, Anna, and Idasiak-Piechocka, Ilona

Subjects
OMEPRAZOLE, KIDNEY transplantation, FAMOTIDINE, H2 receptor antagonists, TACROLIMUS, PHARMACOKINETICS, PROTON pump inhibitors
Abstract

Tacrolimus is metabolized in the liver with the participation of the CYP3A4 and CYP3A5 enzymes. Proton pump inhibitors are used in kidney transplant patients to prevent duodenal and gastric ulcer disease due to glucocorticoids. Omeprazole, unlike famotidine, is a substrate and inhibitor of the enzymes CYP2C19, CYP3A4, CYP3A5. The aim of this study was to compare the impact of omeprazole and famotidine on the pharmacokinetics of tacrolimus. A randomized, non-blinded study involving 22 stabilized adult kidney transplant patients was conducted. Patients received the standard triple immunosuppression regimen and omeprazole 20 mg (n = 10) or famotidine 20 mg (n = 12). The study material consisted of blood samples in which tacrolimus concentrations were determined using the Chemiluminescent Microparticle Immuno Assay method. A single administration of omeprazole increased tacrolimus concentrations at 2 h (day 2) = 11.90 ± 1.59 ng/mL vs. 2 h (day 1 -- no omeprazole administration) = 9.40 ± 0.79 ng/mL (p = 0.0443). AUC0-6 amounted to 63.07 ± 19.46 ng x h/mL (day 2) vs. 54.23 ± 10.48 ng x h/mL (day 1), (p = 0.0295). AUC2-6 amounted to 44.32 ± 11.51 ng x h/mL (day 2) vs. 38.68 ± 7.70 ng x h/mL (day 1), (p = 0.0130). Conversely, no significant changes in values of pharmacokinetic parameters were observed for famotidine. Omeprazole significantly increases blood exposure of tacrolimus. The administration of famotidine instead of omeprazole seems safer for patients following kidney transplantation. Clinical Trial Registration: clinicaltrials.gov, identifier NCT05061303 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. A Rare Case of Dedifferentiated Liposarcoma with Osteosarcomatous Differentiation-Diagnostic and Therapeutic Challenges.

Author

Sosnowska-Sienkiewicz, Patrycja, Mańkowski, Przemysław, Stadnik, Honorata, Dłubak, Agata, Czekała, Anna, and Karczewski, Marek

Subjects
LIPOSARCOMA, KIDNEY tumors, GENE amplification, RETROPERITONEUM, TUMOR treatment, SURGICAL excision, ARACHNOID cysts
Abstract

Introduction: Liposarcomas are the most common of all sarcomas. A well-differentiated liposarcoma can transform into a dedifferentiated liposarcoma with myogenic, osteo- or chondrosarcomatous heterologous differentiation. Genomic amplification of MDM2 gene is then characteristic. Treatment usually involves surgical resection to radically remove the tumor. Other treatments such as chemotherapy and radiotherapy may also be used. Case report: A 60-year-old patient was admitted to the hospital for surgical treatment of a left renal mass. The true location of the tumor was discovered only intraoperatively. The lesion was completely removed laparoscopically with preservation of the capsule. Genomic amplification of MDM2 gene was confirmed. One and a half years after surgery, despite the removal of the tumor without the surrounding margin of healthy tissue, the patient remains without recurrence. Conclusion: Dedifferentiated liposarcoma with osteosarcomatous differentiation is a sporadic case and may occur in various locations of the retroperitoneal space, also mimicking a renal tumor. The laparoscopic technique is a safe surgical treatment for tumors of unclear origin. Removal of dedifferentiated liposarcoma with osteosarcomatous differentiation tumor with preservation of the lesion capsule without maintaining a margin of healthy tissue also allows for long-term cure. Precise immunohistochemical and molecular studies may have an impact on the effectiveness of further treatment and the prognosis of the patient. A patient after surgical treatment of liposarcoma requires constant outpatient follow-up for the reason of the high risk of local and distant recurrence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Creating an Innovative Artificial Intelligence–Based Technology (TCRact) for Designing and Optimizing T Cell Receptors for Use in Cancer Immunotherapies: Protocol for an Observational Trial

Author

Bujak, Joanna, primary, Kłęk, Stanisław, additional, Balawejder, Martyna, additional, Kociniak, Aleksandra, additional, Wilkus, Kinga, additional, Szatanek, Rafał, additional, Orzeszko, Zofia, additional, Welanyk, Joanna, additional, Torbicz, Grzegorz, additional, Jęckowski, Mateusz, additional, Kucharczyk, Tomasz, additional, Wohadlo, Łukasz, additional, Borys, Maciej, additional, Stadnik, Honorata, additional, Wysocki, Michał, additional, Kayser, Magdalena, additional, Słomka, Marta Ewa, additional, Kosmowska, Anna, additional, Horbacka, Karolina, additional, Gach, Tomasz, additional, Markowska, Beata, additional, Kowalczyk, Tomasz, additional, Karoń, Jacek, additional, Karczewski, Marek, additional, Szura, Mirosław, additional, Sanecka-Duin, Anna, additional, and Blum, Agnieszka, additional

Published
2023
Full Text
View/download PDF

10. The Enhanced Expression of ZWILCH Predicts Poor Survival of Adrenocortical Carcinoma Patients

Author

Blatkiewicz, Małgorzata, primary, Kamiński, Kacper, additional, Szyszka, Marta, additional, Al-Shakarchi, Zaid, additional, Olechnowicz, Anna, additional, Stelcer, Ewelina, additional, Komarowska, Hanna, additional, Tyczewska, Marianna, additional, Klimont, Anna, additional, Karczewski, Marek, additional, Wierzbicki, Tomasz, additional, Mikołajczyk-Stecyna, Joanna, additional, Ruchała, Marek, additional, Malendowicz, Ludwik K., additional, and Ruciński, Marcin, additional

Published
2023
Full Text
View/download PDF

11. Creating an Innovative Artificial Intelligence–Based Technology (TCRact) for Designing and Optimizing T Cell Receptors for Use in Cancer Immunotherapies: Protocol for an Observational Trial (Preprint)

Author

Bujak, Joanna, primary, Kłęk, Stanisław, additional, Balawejder, Martyna, additional, Kociniak, Aleksandra, additional, Wilkus, Kinga, additional, Szatanek, Rafał, additional, Orzeszko, Zofia, additional, Welanyk, Joanna, additional, Torbicz, Grzegorz, additional, Jęckowski, Mateusz, additional, Kucharczyk, Tomasz, additional, Wohadlo, Łukasz, additional, Borys, Maciej, additional, Stadnik, Honorata, additional, Wysocki, Michał, additional, Kayser, Magdalena, additional, Słomka, Marta Ewa, additional, Kosmowska, Anna, additional, Horbacka, Karolina, additional, Gach, Tomasz, additional, Markowska, Beata, additional, Kowalczyk, Tomasz, additional, Karoń, Jacek, additional, Karczewski, Marek, additional, Szura, Mirosław, additional, Sanecka-Duin, Anna, additional, and Blum, Agnieszka, additional

Published
2023
Full Text
View/download PDF

13. Longitudinal Evaluation of Biomarkers in Wound Fluids from Venous Leg Ulcers and Split-thickness Skin Graft Donor Site Wounds Treated with a Protease-modulating Wound Dressing

Author

Mikosiński, Jacek, primary, Kalogeropoulos, Konstantinos, additional, Bundgaard, Louise, additional, Larsen, Cathrine Agnete, additional, Savickas, Simonas, additional, Moldt Haack, Aleksander, additional, Pańczak, Konrad, additional, Rybołowicz, Katarzyna, additional, Grzela, Tomasz, additional, Olszewski, Michał, additional, Ciszewski, Piotr, additional, Sitek-Ziółkowska, Karina, additional, Twardowska-Saucha, Krystyna, additional, Karczewski, Marek, additional, Rabczenko, Daniel, additional, Segiet, Agnieszka, additional, Buczak-Kula, Patrycja, additional, Schoof, Erwin M., additional, Eming, Sabine A., additional, Smola, Hans, additional, and Auf dem Keller, Ulrich, additional

Published
2022
Full Text
View/download PDF

16. Biological response of adrenal carcinoma and melanoma cells to mitotane treatment

Author

Stelcer, Ewelina, primary, Komarowska, Hanna, additional, Jopek, Karol, additional, Żok, Agnieszka, additional, Iżycki, Dariusz, additional, Malińska, Agnieszka, additional, Szczepaniak, Beata, additional, Komekbai, Zhanat, additional, Karczewski, Marek, additional, Wierzbicki, Tomasz, additional, Suchorska, Wiktoria, additional, Ruchała, Marek, additional, and Ruciński, Marcin, additional

Published
2022
Full Text
View/download PDF

17. Angiogenic Role of Mesothelium-Derived Chemokine CXCL1 During Unfavorable Peritoneal Tissue Remodeling in Patients Receiving Peritoneal Dialysis as Renal Replacement Therapy

Author

Catar, Rusan Ali, primary, Bartosova, Maria, additional, Kawka, Edyta, additional, Chen, Lei, additional, Marinovic, Iva, additional, Zhang, Conghui, additional, Zhao, Hongfan, additional, Wu, Dashan, additional, Zickler, Daniel, additional, Stadnik, Honorata, additional, Karczewski, Marek, additional, Kamhieh-Milz, Julian, additional, Jörres, Achim, additional, Moll, Guido, additional, Schmitt, Claus Peter, additional, and Witowski, Janusz, additional

Published
2022
Full Text
View/download PDF

18. Angiogenic Role of Mesothelium-Derived Chemokine CXCL1 During Unfavorable Peritoneal Tissue Remodeling in Patients Receiving Peritoneal Dialysis as Renal Replacement Therapy

Author

Catar, Rusan Ali, Bartosova, Maria, Kawka, Edyta, Chen, Lei, Marinovic, Iva, Zhang, Conghui, Zhao, Hongfan, Wu, Dashan, Zickler, Daniel, Stadnik, Honorata, Karczewski, Marek, Kamhieh-Milz, Julian, Jörres, Achim, Moll, Guido, Schmitt, Claus Peter, and Witowski, Janusz

Subjects
Vascular Endothelial Growth Factor A, Neovascularization, Pathologic, Chemokine CXCL1, Interleukin-17, COVID-19, Infant, Vascular Remodeling, Epithelium, Renal Replacement Therapy, angiogenesis, end-stage renal disease (ESRD), mesothelium, Child, Preschool, cytokine/chemokine-signaling, Humans, Kidney Failure, Chronic, CXC chemokine ligand 1 (CXCL1), Peritoneum, interleukin 17, Child, peritoneal dialysis (PD), Peritoneal Dialysis, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, Cells, Cultured
Abstract

Peritoneal dialysis (PD) is a valuable 'home treatment' option, even more so during the ongoing Coronavirus pandemic. However, the long-term use of PD is limited by unfavourable tissue remodelling in the peritoneal membrane, which is associated with inflammation-induced angiogenesis. This appears to be driven primarily through vascular endothelial growth factor (VEGF), while the involvement of other angiogenic signaling pathways is still poorly understood. Here, we have identified the crucial contribution of mesothelial cell-derived angiogenic CXC chemokine ligand 1 (CXCL1) to peritoneal angiogenesis in PD. CXCL1 expression and peritoneal microvessel density were analysed in biopsies obtained by the International Peritoneal Biobank (NCT01893710 at www.clinicaltrials.gov), comparing 13 children with end-stage kidney disease before initiating PD to 43 children on chronic PD. The angiogenic potential of mesothelial cell-derived CXCL1 was assessed in vitro by measuring endothelial tube formation of human microvascular endothelial cells (HMECs) treated with conditioned medium from human peritoneal mesothelial cells (HPMCs) stimulated to release CXCL1 by treatment with either recombinant IL-17 or PD effluent. We found that the capillary density in the human peritoneum correlated with local CXCL1 expression. Both CXCL1 expression and microvessel density were higher in PD patients than in the age-matched patients prior to initiation of PD. Exposure of HMECs to recombinant CXCL1 or conditioned medium from IL-17-stimulated HPMCs resulted in increased endothelial tube formation, while selective inhibition of mesothelial CXCL1 production by specific antibodies or through silencing of relevant transcription factors abolished the proangiogenic effect of HPMC-conditioned medium. In conclusion, peritoneal mesothelium-derived CXCL1 promotes endothelial tube formation in vitro and associates with peritoneal microvessel density in uremic patients undergoing PD, thus providing novel targets for therapeutic intervention to prolong PD therapy.

Published
2021

21. Evaluation of LL‐37 in healing of hard‐to‐heal venous leg ulcers: A multicentric prospective randomized placebo‐controlled clinical trial

Author

Mahlapuu, Margit, primary, Sidorowicz, Adam, additional, Mikosinski, Jacek, additional, Krzyżanowski, Mikołaj, additional, Orleanski, Jakub, additional, Twardowska‐Saucha, Krystyna, additional, Nykaza, Andrzej, additional, Dyaczynski, Michal, additional, Belz‐Lagoda, Beata, additional, Dziwiszek, Grzegorz, additional, Kujawiak, Monika, additional, Karczewski, Marek, additional, Sjöberg, Folke, additional, Grzela, Tomasz, additional, Wegrzynowski, Adam, additional, Thunarf, Fredrik, additional, Björk, Jakob, additional, Ekblom, Jonas, additional, Jawien, Arkadiusz, additional, and Apelqvist, Jan, additional

Published
2021
Full Text
View/download PDF

22. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials

Author

David T Rubin, Iris Dotan, Aaron DuVall, Yoram Bouhnik, Graham Radford-Smith, Peter D R Higgins, Daniel S Mishkin, Pablo Arrisi, Astrid Scalori, Young S Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Stuart Lacey, Jacqueline McBride, Julian Panés, Abdulkhakov Rustem, Abu Bakar Norasiah, Aguilar Humberto, Aizenberg Diego, Akpinar Hale, Akriviadis Evangelos, Alexeeva Olga, Alikhanov Bagdadi, Alvarisqueta Andres, Ananthakrishnan Ashwin, Andrews Jane, Arlukowicz Tomasz, Atkinson Nathan, Atug Ozlen, Bafutto Mauro, Balaz Jozef, Bamias George, Banic Marko, Baranovsky Andrey, Barbalaco Neto Guerino, Basaranoglu Metin, Baum Curtis, Baydanov Stefan, Bennetts William, Besisik Fatih, Bhaskar Sudhir, Bielasik Andrzej, Bilianskyi Leonid, Bilir Bahri, Blaha Pavol, Bohman Verle, Borissova Julia, Borzan Vladimir, Bosques-Padilla Francisco, Bouhnik Yoram, Brooker James, Budko Tetiana, Budzak Igor, Bunganic Ivan, Chapman Jonathon, Che' Aun Azlida, Chernykh Tatiana, Chiorean Michael, Chopey Ivan, Christodoulou Dimitrios, Chu Pui Shan, Chumakova Galina, Cummins Andrew, Cunliffe Robert, Cvetkovic Mirjana, Dagli Ulku, Danilkiewicz Wit Cezary, Datsenko Olena, de Magalhães Francesconi Carlos Fernando, Debinski Henry, Deminova Elena, Derova Jelena, Ding John Nik, Dmitrieva Julia, Dolgikh Oleg, Douda Tomas, Drobinski Piotr, Dryden Gerald, Duarte Gaburri Pedro, DuVall George Aaron, Dvorkin Mikhail, Ennis Craig, Erzin Yusuf, Fadieienko Galyna, Fediv Oleksandr, Fedorishina Olga, Fedurco Miroslav, Fejes Roland, Fernandez Jorge, Fernandez Monica Lorena, Flores Lucky, Freilich Bradley, Friedenberg Keith, Fuster Sergio, Gawdis-Wojnarska Beata, Gil Parada Fabio Leonel, Gimenez Edgardo Daniel, Golovchenko Nataliia, Golovchenko Oleksandr, Gonciarz Maciej, Gonen Can, Gordon Glenn, Gregus Milos, Grinevich Vladimir, Guajardo Rodriguez Rogelio, Hall Stephen, Hanson John, Hartleb Marek, Hebuterne Xavier, Hendy Peter, Herring Robert, Hetzel David, Higgins Peter, Hilal Raouf, Hilmi Ida Normiha, Hlavaty Tibor, Holman Richard, Holtmann Gerald, Hong John, Horvath Frantisek, Hospodarskyy Ihor, Hrstic Irena, Hulagu Sadettin, Ibarra Verdugo Luis Alberto, Ibegbu Ikechukwu, Inns Stephen, Ivashkin Vladimir, Izanec James, Jain Rajesh, Jamrozik-Kruk Zofia, Kamburov Victor, Karagiannis John, Karakan Tarkan, Karczewski Marek, Kasherininova Irina, Katz Seymour, Kaufman Barry, Kazenaite Edita, Kholina Irina, Khurana Sunil, Kierkus Jaroslaw, Kiselevska Anzela, Kleczkowski Dariusz, Klymenko Volodymyr, Knezevic Slavko, Kondusz-Szklarz Malgorzata, Korablina Natalya, Korczowski Bartosz, Kosturkov Lyubomir, Kotzev Iskren, Kouklakis Georgios, Koutroubakis Ioannis, Krause Richard, Kronborg Ian, Krstic Miodrag, Krznaric Zeljko, Krzyzanowski Mikolaj, Kulig Grazyna, Kull Karin, Kupcinskas Limas, Lamet Mark, Latinovic Radakovic Tatjana, Leong Rupert, Leung Wai Keung, Levine Henry, Li Michael Kin Kong, Libanez Bessa Campelo Braga Lúcia, Livzan Maria, Lohdanidi Tetiana, Louzada Pereira Maria Helena, Lowe John, Luetic Kresimir, Lukas Milan, Lymar Yurii, Macrae Finlay, Mäelt Anu, Maev Igor, Mamos Arkadiusz, Mantzaris Gerasimos, Margus Benno, Marinova Ivanka, Markevych Inna, Markov Mario, Markovic Srdjan, Marquez Velasquez Juan Ricardo, Mazzoleni Felipe, Mimidis Konstantinos, Mitchell Brent, Moore Gregory, Morales Garza Luis Alonso, Moscatello Salvatore, Mostovoy Yuriy, Mountifield Reme, Nagorni Aleksandar, Neshta Viacheslav, Obrezan Andrey, Oliinyk Oleksandr, Oliveira Santana Silva Genoile, Orzeszko Maria, Pavlenko Vladimir, Pavlov Dimitar, Penkova Mariana, Peric Sasa, Petkov Plamen, Petrov Asen, Petrov Plamen, Petrova Michaela, Phillips Raymond, Pintor Chacon Sergio, Polianskyi Igor, Prystupa Ludmyla, Pugach Mykhailo, Pugas Carvalho Ana Teresa, Pukitis Aldis, Pumprla Jiri, Pyrogovskyy Volodymyr, Racz Istvan, Radford-Smith Graham, Raja Ali Raja Affendi, Ramos Castañeda Daniel, Ramos Júnior Odery, Rausher David, Rebrov Andrey, Regula Jaroslaw, Rezk Amir, Reznikova Viktoriia, Rishko Iaroslava, Roblin Xavier, Rodoman Grigory, Rojas Rodriguez Carlos Arturo, Rozciecha Jerzy, Rubin David, Rupinski Maciej, Rzucidlo Jacek, Sablin Oleg, Sahin Halil, Salleh Rosemi, Samuel Douglas, Scafuto Scotton Antonio, Schnabel Robert, Schulman Michael, Schultz Michael, Scott John, Sedghi Shahriar, Shaban Ahmad, Shapina Marina, Shaposhnikova Natalia, Shchukina Oksana, Sherman Alex, Shumikhina Irina, Simanenkov Vladimir, Simonov Vladislav, Simulionis Giedrius, Skrypnyk Igor, Sliwowski Zbigniew, Smid Jan, Solaiman Mahmood, Soofi Najm, Soufleris Konstantinos, Spassova Zoia, Stanislavchuk Mykola, Stec-Michalska Krystyna, Stifft Jonathas, Stoinov Simeon, Stoyanova Girgina, Sultan Keith, Surace Lindsey, Takov Dimitar, Tälli Jaak, Tankova Ludmila, Tanno Hugo, Tarabar Dino, Tarakji Elias, Tchernev Konstantin, Tee Hoi Poh, Thin Lena, Thomas Carlton, Tishaeva Irina, Todorova Tsveta, Tokarenko Oleksandr, Tolmanis Ivars, Tomasevic Ratko, Trofimov Vasiliy, Tulassay Zsolt, Unsal Belkis, Uzunova-Genova Alma, Valentine John, Valuyskikh Ekaterina, Vasconcellos Eduardo, Vasileva Galina, Vasylyuk Sergiy, Vaughn Byron, Velazquez Francisco, Vizir Vadym, Vladimirov Borislav, Volfova Miroslava, Vyhnalek Petr, Wallace Ian, Waluga Marek, Watkins William, Weber John, Wiechowska-Kozlowska Anna, Winstead Nathaniel, Wojtkiewicz Pawel, Wozniak-Stolarska Barbara, Yacyshyn Bruce, Yakovlev Alexey, Younes Ziad, Yukie Sassaki Lígia, Yuksel Ilhami, Zachar Jan, Zaltman Cyrla, Zdravkovic Petrovic Natasa, Zhdan Vyacheslav, Zinchenko Maryna, and Zymla Maciej

Subjects
Ulcerative Colitis Flare, Adult, Male, medicine.medical_specialty, Adolescent, Population, Placebo, Antibodies, Monoclonal, Humanized, Gastroenterology, Severity of Illness Index, Placebos, Young Adult, Double-Blind Method, Gastrointestinal Agents, Internal medicine, Adalimumab, Medicine, Humans, Adverse effect, education, Aged, education.field_of_study, Hepatology, business.industry, Remission Induction, Colonoscopy, Induction Chemotherapy, Middle Aged, medicine.disease, Symptom Flare Up, Ulcerative colitis, Concomitant, Etrolizumab, Colitis, Ulcerative, Female, business, medicine.drug
Abstract

Summary Background Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In an earlier phase 2 induction study, etrolizumab significantly improved clinical remission relative to placebo in patients with moderately to severely active ulcerative colitis. The HIBISCUS studies aimed to compare the efficacy and safety of etrolizumab to adalimumab and placebo for induction of remission in patients with moderately to severely active ulcerative colitis. Methods HIBISCUS I and HIBISCUS II were identically designed, multicentre, phase 3, randomised, double-blind, placebo-controlled and active-controlled studies of etrolizumab, adalimumab, and placebo in adult (18–80 years) patients with moderately to severely active ulcerative colitis (Mayo Clinic total score [MCS] of 6–12 with an endoscopic subscore of ≥2, a rectal bleeding subscore of ≥1, and a stool frequency subscore of ≥1) who were naive to tumour necrosis factor inhibitors. All patients had an established diagnosis of ulcerative colitis for at least 3 months, corroborated by both clinical and endoscopic evidence, and evidence of disease extending at least 20 cm from the anal verge. In both studies, patients were randomly assigned (2:2:1) to receive subcutaneous etrolizumab 105 mg once every 4 weeks; subcutaneous adalimumab 160 mg on day 1, 80 mg at week 2, and 40 mg at weeks 4, 6, and 8; or placebo. Randomisation was stratified by baseline concomitant treatment with corticosteroids, concomitant treatment with immunosuppressants, and baseline disease activity. All patients and study site personnel were masked to treatment assignment. The primary endpoint was induction of remission at week 10 (defined as MCS of 2 or lower, with individual subscores of 1 or lower, and rectal bleeding subscore of 0) with etrolizumab compared with placebo. Pooled analyses of both studies comparing etrolizumab and adalimumab were examined for several clinical and endoscopic endpoints. Efficacy was analysed using a modified intent-to-treat population, defined as all randomly assigned patients who received at least one dose of study drug. These trials are registered with ClinicalTrials.gov , NCT02163759 (HIBISCUS I), NCT02171429 (HIBISCUS II). Findings Between Nov 4, 2014, and May 25, 2020, each study screened 652 patients (HIBISCUS I) and 613 patients (HIBISCUS II). Each study enrolled and randomly assigned 358 patients (HIBISCUS I etrolizumab n=144, adalimumab n=142, placebo n=72; HIBISCUS II etrolizumab n=143; adalimumab n=143; placebo n=72). In HIBISCUS I, 28 (19·4%) of 144 patients in the etrolizumab group and five (6·9%) of 72 patients in the placebo group were in remission at week 10, with an adjusted treatment difference of 12·3% (95% CI 1·6 to 20·6; p=0·017) in favour of etrolizumab. In HIBISCUS II, 26 (18·2%) of 143 patients in the etrolizumab group and eight (11·1%) of 72 patients in the placebo group were in remission at week 10, with an adjusted treatment difference of 7·2% (95% CI –3·8 to 16·1; p=0·17). In the pooled analysis, etrolizumab was not superior to adalimumab for induction of remission, endoscopic improvement, clinical response, histological remission, or endoscopic remission; however, similar numerical results were observed in both groups. In HIBISCUS I, 50 (35%) of 144 patients in the etrolizumab group reported any adverse event, compared with 61 (43%) of 142 in the adalimumab group and 26 (36%) of 72 in the placebo group. In HIBISCUS II, 63 (44%) of 143 patients in the etrolizumab group reported any adverse event, as did 62 (43%) of 143 in the adalimumab group and 33 (46%) in the placebo group. The most common adverse event in all groups was ulcerative colitis flare. The incidence of serious adverse events in the pooled patient population was similar for etrolizumab (15 [5%] of 287) and placebo (seven [5%] of 144) and lower for adalimumab (six [2%] of 285). Two patients in the etrolizumab group died; neither death was deemed to be treatment related. Interpretation Etrolizumab was superior to placebo for induction of remission in HIBISCUS I, but not in HIBISCUS II. Etrolizumab was well tolerated in both studies. Funding F Hoffmann-La Roche.

Published
2021

23. Abnormal Nailfold Capillaries in Patients after Hand Transplantation

Author

Sikorska, Dorota, primary, Samborski, Włodzimierz, additional, Kamińska, Dorota, additional, Kusztal, Mariusz, additional, Jabłecki, Jerzy, additional, Nijakowski, Kacper, additional, Oko, Andrzej, additional, Karczewski, Marek, additional, Korybalska, Katarzyna, additional, and Witowski, Janusz, additional

Published
2020
Full Text
View/download PDF

24. Adropin Stimulates Proliferation and Inhibits Adrenocortical Steroidogenesis in the Human Adrenal Carcinoma (HAC15) Cell Line

Author

Stelcer, Ewelina, primary, Milecka, Paulina, additional, Komarowska, Hanna, additional, Jopek, Karol, additional, Tyczewska, Marianna, additional, Szyszka, Marta, additional, Lesniczak, Marta, additional, Suchorska, Wiktoria, additional, Bekova, Karlygash, additional, Szczepaniak, Beata, additional, Ruchala, Marek, additional, Karczewski, Marek, additional, Wierzbicki, Tomasz, additional, Szaflarski, Witold, additional, Malendowicz, Ludwik K., additional, and Rucinski, Marcin, additional

Published
2020
Full Text
View/download PDF

26. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohnʼs disease: unexpected results of a randomised, double-blind placebo-controlled trial

Author

Hueber, Wolfgang, Sands, Bruce E, Lewitzky, Steve, Vandemeulebroecke, Marc, Reinisch, Walter, Higgins, Peter D R, Wehkamp, Jan, Feagan, Brian G, Yao, Michael D, Karczewski, Marek, Karczewski, Jacek, Pezous, Nicole, Bek, Stephan, Bruin, Gerard, Mellgard, Bjoern, Berger, Claudia, Londei, Marco, Bertolino, Arthur P, Tougas, Gervais, and Travis, Simon P L

Published
2012
Full Text
View/download PDF

34. Ghrelin as a potential molecular marker of adrenal carcinogenesis: In vivo and in vitro evidence

Author

Komarowska, Hanna, primary, Rucinski, Marcin, additional, Tyczewska, Marianna, additional, Sawicka-Gutaj, Nadia, additional, Szyszka, Marta, additional, Hernik, Aleksandra, additional, Klimont, Anna, additional, Milecka, Paulina, additional, Migasiuk, Laura, additional, Biczysko, Mateusz, additional, Idasiak-Piechocka, Ilona, additional, Karczewski, Marek, additional, and Ruchala, Marek, additional

Published
2018
Full Text
View/download PDF

35. Ghrelin is overexpressed in adrenal cancers and stimulates proliferation and migration of ACC cell line.

Author

Komarowska, Hanna, primary, Rucinski, Marcin, additional, Tyczewska, Marianna, additional, Sawicka-Gutaj, Nadia, additional, Szyszka, Marta, additional, Hernik, Aleksandra, additional, Klimont, Anna, additional, Milecka, Paulina, additional, Migasiuk, Laura, additional, Biczysko, Mateusz, additional, Idasiak-Piechocka, Ilona, additional, Karczewski, Marek, additional, Czarnywojtek, Agata, additional, and Ruchala, Marek, additional

Published
2018
Full Text
View/download PDF

38. High-fidelity simulation — the first DCD-ECMO procedure in Poland

Author

Puslecki, Mateusz, primary, Ligowski, Marcin, additional, Dabrowski, Marek, additional, Sip, Maciej, additional, Stefaniak, Sebastian, additional, Klosiewicz, Tomasz, additional, Gasiorowski, Lukasz, additional, Karczewski, Marek, additional, Malkiewicz, Tomasz, additional, Ladzinska, Malgorzata, additional, Zielinski, Marcin, additional, Pawlak, Aleksander, additional, Dabrowska, Agata, additional, Ziemak, Piotr, additional, Perek, Bartlomiej, additional, Misterski, Marcin, additional, Katarzynski, Slawomir, additional, Buczkowski, Piotr, additional, Telec, Wojciech, additional, Kiel-Puslecka, Ilona, additional, Kiel, Michal, additional, Czekajlo, Michael, additional, and Jemielity, Marek, additional

Published
2017
Full Text
View/download PDF

39. Using simulation to create a unique regional ECMO program for the Greater Poland region

Author

Puślecki, Mateusz, primary, Ligowski, Marcin, additional, Stefaniak, Sebastian, additional, Zieliński, Marcin, additional, Pawlak, Aleksander, additional, Dąbrowski, Marek, additional, Kłosiewicz, Tomasz, additional, Sip, Maciej, additional, Karczewski, Marek, additional, Małkiewicz, Tomasz, additional, Gąsiorowski, Łukasz, additional, Telec, Wojciech, additional, Ładzińska, Małgorzata, additional, Ładziński, Piotr, additional, Perek, Bartłomiej, additional, Misterski, Marcin, additional, Mrówczyński, Wojciech, additional, Sobczyński, Paweł, additional, Panieński, Paweł, additional, Łukasik-Głębocka, Magdalena, additional, Artyńska, Aniela, additional, Gezela, Mariusz, additional, Buczkowski, Piotr, additional, Czekajlo, Michael, additional, and Jemielity, Marek, additional

Published
2017
Full Text
View/download PDF

41. The role of extracorporeal membrane oxygenation in patients after irreversible cardiac arrest as potential organ donors

Author

Kłosiewicz, Tomasz, primary, Puślecki, Mateusz, additional, Zieliński, Marcin, additional, Mandecki, Michał, additional, Ligowski, Marcin, additional, Stefaniak, Sebastian, additional, Dąbrowski, Marek, additional, Karczewski, Marek, additional, Gąsiorowski, Łukasz, additional, Sip, Maciej, additional, Dąbrowska, Agata, additional, Telec, Wojciech, additional, Perek, Bartłomiej, additional, and Jemielity, Marek, additional

Published
2017
Full Text
View/download PDF

43. Scaffolds from Surgically Removed Kidneys as a Potential Source of Organ Transplantation

Author

Karczewski, Marek and Malkiewicz, Tomasz

Subjects
Article Subject
Abstract

End stage renal disease (ESRD) is a common disease, which relates to nearly 600 million people in the total population. What is more, it seems to be a crucial problem from the epidemiological point of view. These facts lead to a further necessity of renal replacement therapy development connected with rising expenditures for the health care system. The aim of kidney tissue engineering is to develop and innovate methods of obtaining renal extracellular matrix (ECM) scaffolds derived from kidney decellularization. Recently, progress has been made towards developing a functional kidney graft in vitro on demand. In fact, decellularized tissues constitute ideal natural scaffolds, due to the preservation of native ECM architecture, as well as of cell-ECM binding domains critical in promoting cell attachment, migration, and proliferation. One of the potential sources of the natural scaffolds is the kidney, which cannot be transplanted immediately after excision.

Published
2015
Full Text
View/download PDF

44. SYMBOL WĘŻA WAPOKALIPSIE ŚWIĘTEGO JANA.

Author

KARCZEWSKI, MAREK

Abstract

Copyright of Studia Nauk Teologicznych PAN is the property of Polish Academy of Sciences, Committee on Theological Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results